Chief Medical Officer, Florida Blood Services and Creative Testing Solutions (Former CEO of Florida Blood Services)
Dr. Leparc graduated with an M.D. degree from the National University of La Plata, Argentina. Upon graduation, he received an appointment as Research Fellow at the Scientific Research Commission of the Province of Buenos Aires, where he conducted studies on Hemolytic-Uremic Syndrome (HUS). He received postgraduate medical training in Pathology and Laboratory Medicine at the University of South Florida College of Medicine. He is Board certified in Anatomic and Clinical Pathology, as well as in Blood Banking/Transfusion Medicine. As Chief Medical Officer for Florida Blood Services (FBS), Dr. Leparc has medical oversight over blood collections in the Tampa Bay Area, Florida’s panhandle region and southern Georgia. This region collects 175,000-350,000 donations per year represents approximately 1.2% of the nation’s blood supply. FBS laboratories, located in St. Petersburg, serve as a donor blood screening services for several blood centers along the U.S. East Coast, and test close to 86% of the nation’s blood supply. FBS has a significant presence in the United States and is currently the nation’s third largest supplier of blood and the second largest donor testing facility.
Dr. Leparc has participated in pivotal studies leading to licensure of nucleic acid testing for transmissible disease markers, as well as in the NIH-sponsored “Retrovirus Epidemiologic Donor Study (REDS) Allogeneic Donor and Recipient Repository.” As former President of the Florida Association of Blood Banks, current past member of the Board of Directors of the American Association of Blood Banks (AABB), associate Clinical Professor in the Department of Internal Medicine and the Department of Laboratory Medicine and Cellular Biology at the USF College of Medicine, and author of over 540 peer-reviewed scientific papers, Dr. Leparc has a comprehensive understanding of current analytical technologies for pathogen detection in blood. By leveraging his experience in the development of assays and new devices, he also makes important contributions to defining Claro’s clinical and regulatory strategies.